How Will Fujifilm (FUJIY) Stock Be Boosted By Ebola Drug Approval?

NEW YORK (TheStreet) -- Shares of Fujifilm Holdings Corp. (FUJIY) are up 8.83% to $30.92 after it was reported that U.S. government researchers are working to get an experimental flu drug from the Japan-based company quickly approved to treat Ebola, as the death toll in West Africa increases, Bloomberg reports..

Fujifilm's U.S. partner MediVector Inc. in Boston is in talks with the FDA to submit an application to use the drug in humans for Ebola, according to the Defense Department. If successful, the treatment drug would be one of the first allowed by U.S. regulators to fight the disease in humans, Bloomberg said.

The DOD prioritized the completion of a study that tests the drug called favipiravir in Ebola-infected monkeys. The drug can be fast-tracked through the regulatory review process after the studies are complete, and preliminary monkey data are expected in mid-September.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

FUJIY ChartFUJIY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon